Literature DB >> 10837706

Highly soluble cyclodextrin derivatives: chemistry, properties, and trends in development.

.   

Abstract

As the first pharmaceutical products which contain highly soluble cyclodextrin (CD) derivatives (e.g. Sporanox=itraconazole/HP-beta-CD by Janssen and Clorocil=chloramphenicol/methyl-beta-CD by Oftalder) are already on the market it seems to be timely to give an overview on the technological and commercial aspects of the chemically modified water-soluble CDs as drug carriers. This chapter deals with the chemistry and general properties of water-soluble CDs and follows the trends in their development. The quality requirements of industrially relevant water-soluble CDs together with the quality-assurance-related analytical techniques, are thought help understand how difficult the characterization and approval processes of such novel excipients are. Literature data taken from Cyclolab's databank support the validity of statements in evaluation of trends of development of CD derivatives as pharmaceutical excipients.

Entities:  

Year:  1999        PMID: 10837706     DOI: 10.1016/s0169-409x(98)00092-1

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  70 in total

1.  Host-guest interactions mediated nano-assemblies using cyclodextrin-containing hydrophilic polymers and their biomedical applications.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Nano Today       Date:  2010-08-01       Impact factor: 20.722

2.  Dense gas processing of micron-sized drug formulations incorporating hydroxypropylated and methylated beta-cyclodextrin.

Authors:  Raffaella Mammucari; Fariba Dehghani; Neil R Foster
Journal:  Pharm Res       Date:  2006-01-01       Impact factor: 4.200

Review 3.  Advanced technologies for oral controlled release: cyclodextrins for oral controlled release.

Authors:  Paulo José Salústio; Patrícia Pontes; Claúdia Conduto; Inês Sanches; Catarina Carvalho; João Arrais; Helena M Cabral Marques
Journal:  AAPS PharmSciTech       Date:  2011-09-27       Impact factor: 3.246

4.  Development and validation of sensitive LC-MS/MS assays for quantification of HP-β-CD in human plasma and CSF.

Authors:  Hui Jiang; Rohini Sidhu; Hideji Fujiwara; Marc De Meulder; Ronald de Vries; Yong Gong; Mark Kao; Forbes D Porter; Nicole M Yanjanin; Nuria Carillo-Carasco; Xin Xu; Elizabeth Ottinger; Myra Woolery; Daniel S Ory; Xuntian Jiang
Journal:  J Lipid Res       Date:  2014-05-27       Impact factor: 5.922

5.  Acyclic cucurbit[n]uril molecular containers enhance the solubility and bioactivity of poorly soluble pharmaceuticals.

Authors:  Da Ma; Gaya Hettiarachchi; Duc Nguyen; Ben Zhang; James B Wittenberg; Peter Y Zavalij; Volker Briken; Lyle Isaacs
Journal:  Nat Chem       Date:  2012-04-15       Impact factor: 24.427

6.  Study of isopropyl myristate microemulsion systems containing cyclodextrins to improve the solubility of 2 model hydrophobic drugs.

Authors:  Indranil Nandi; Mohammad Bari; Hemant Joshi
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

7.  Structural behaviour of 2-hydroxypropyl-beta-cyclodextrin in water: molecular dynamics simulation studies.

Authors:  Chin Weng Yong; Clive Washington; William Smith
Journal:  Pharm Res       Date:  2007-12-28       Impact factor: 4.200

Review 8.  Cyclodextrin-based supramolecular systems for drug delivery: recent progress and future perspective.

Authors:  Jianxiang Zhang; Peter X Ma
Journal:  Adv Drug Deliv Rev       Date:  2013-05-11       Impact factor: 15.470

9.  Effect of cyclodextrins on the complexation and nasal permeation of melatonin.

Authors:  R Jayachandra Babu; Pankaj Dayal; Mandip Singh
Journal:  Drug Deliv       Date:  2008-08       Impact factor: 6.419

10.  Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent.

Authors:  Mark Welliver; John McDonough; Nicholas Kalynych; Robert Redfern
Journal:  Drug Des Devel Ther       Date:  2009-02-06       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.